• Molecular NameZaleplon
  • SynonymDEA No; 2781; zaleplon
  • Weight305.341
  • Drugbank_IDDB00962
  • ACS_NO151319-34-5
  • Show 3D model
  • LogP (experiment)1.23
  • LogP (predicted, AB/LogP v2.0)1.95
  • pkaN/A
  • LogD (pH=7, predicted)1.95
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.58
  • LogSw (predicted, AB/LogsW2.0)0.13
  • Sw (mg/ml) (predicted, ACD/Labs)0.08
  • No.of HBond Donors0
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds4
  • TPSA74.28
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA sedative/hypnotic, mainly used for insomnia.
  • Absorption_value100.0
  • Absorption (description)Absorption Zaleplon is rapidly and almost completely absorbed following oral administration.
  • Caco_2N/A
  • Bioavailability31.0
  • Protein binding60.0
  • Volume of distribution (VD)1.3 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmZaleplon is primarily metabolised by aldehyde oxidase, and its half-life can be affected by substances which inhibit or induce aldehyde oxidase. It is extensively metabolised, into 5-oxo-zaleplon and 5-oxo-desethylzaleplon (the latter via desethylzaleplon), with less than 1% of it excreted intact in urine.
  • Half life1 h
  • ExcretionRenal
  • Urinary Excretion<1
  • Clerance15.7 ml/min/kg
  • ToxicitySide effects include abdominal pain, amnesia, dizziness, drowsiness, eye pain, headache, memory loss, menstrual pain, nausea, sleepiness, tingling, weakness
  • LD50 (rat)N/A
  • LD50 (mouse)N/A